Advertisement

Advertisement
Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

CHRONOS-3: Addition of Copanlisib to Rituximab Extends Progression-Free Survival in Relapsed Indolent NHL

CHRONOS-3: Addition of Copanlisib to Rituximab Extends Progression-Free 
Survival in Relapsed Indolent NHL

The combination of the PI3K inhibitor copanlisib plus the monoclonal antibody rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (NHL), according to the results of the phase III CHRONOS-3 trial presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting 2021. Trial results were also published in The Lancet Oncology to coincide with the presentation.

Diagnosis-to-Treatment Interval and Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma

Diagnosis-to-Treatment Interval and Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma

In a study reported in the Journal of Clinical Oncology, Stefan Alig, MD, and colleagues found that a short diagnosis-to-treatment interval in patients with diffuse large B-cell lymphoma was associated with higher baseline tumor burden, reflected in higher pretreatment circulating tumor DNA levels.

Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Early-Stage Unfavorable-Risk Hodgkin Lymphoma

In a pilot study reported in the Journal of Clinical Oncology, Kumar et al found that the combination of brentuximab vedotin with AVD (doxorubicin, vinblastine, and dacarbazine) was highly active in patients with newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma and may permit the reduction or avoidance of consolidative radiotherapy in this setting.

Glofitamab for Relapsed or Refractory B-Cell Lymphoma

In a phase I trial reported in the Journal of Clinical Oncology, Hutchings et al found that the bivalent CD20-targeting T-cell–engaging bispecific antibody glofitamab produced high response rates and was associated with manageable toxicity in patients with predominantly refractory aggressive B-cell non-Hodgkin lymphoma.

Integration of Brentuximab Vedotin Into Front-Line Treatment for Pediatric Patients With High-Risk Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Metzger et al found that the integration of brentuximab vedotin into front-line treatment of pediatric patients with high-risk classical Hodgkin lymphoma resulted in avoidance of radiotherapy in many patients, as well as high rates of event-free and overall survival.

Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was well tolerated and showed signs of clinical efficacy in patients with relapsed/refractory B-cell lymphoma, according to phase I clinical trial data presented by Ghafouri et al during the AACR Annual Meeting 2021.

Advertisement


Advertisement